References
- Van Zyl-Smit R. Diagnosis and management of iron deficiency in chronic dialysis patients. Curr Opin Nephrol Hypertens 2000; 9: 669–74.
- Besarab A, Amin N, Ahsan M, Vogel S, Zazuwa G, Frinak S, Zazra J, Anandan J, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530–8.
- Cullen P, Söffker J, Höpfl M, Bremer C, Schlaghecken R, Mehrens T, Assmann G, Schaefer R. Hypochromic red cells and reticulo-cyte haemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 1999; 14: 659–65.
- Tsuchiya K, Okano H, Teramura M, Iwamoto Y, Yamashita N, Suda A, Shimada K, Nihei H, Ando M. Content of reticulocyte hemoglobin is a reliable tool for determing iron deficiency in dialysis patients. Clin Nephrol 2003; 59: 115–23.
- Schaefer RM, Schaefer L. Hypochromic red blood cells and reticulocytes. Kidney Int 1999; 55 Suppl 69: S44–8.
- Mittmann N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, Avram M. Reticulocyte hemoglobin content pre-dicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis 1997; 30: 912–22.
- Macdougall IC. What is the most appropriate strategy to monitor functional iron deficiency in the dialyzed patient on rhEPO therapy? Nephrol Dial Transplant 1998; 13: 847–9.
- Lorenzo JD, Rodriguez MM, Martin SS, Romo JMT. Assessment of erythropoiesis activity during hemodialysis therapy by soluble transferrin recep-tor levels and ferro kinetic measurements. Am J Kidney Dis 2001; 37: 550–6.
- D'Onofrio G, Chirillo R, Zini G, Caenaro G, Tommasi M, Micciulli G. Simultaneous measure-ment of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. Blood 1995; 3: 818–23.
- Goodnough LT, Skikne B, Brugnara C. Erythro-poietin, iron, and erythropoiesis. Blood 2000; 96: 823— 33.
- Brugnara C, Colella GM, Cremins J, Langley RC, Schneider TJ, Rutherford CJ, Goldberg MA. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994; 123: 660–7.
- Fishbane S, Galgano C, Langley RC, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997; 52: 217–22.
- Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS. Red blood cell regeneration induced by subcutaneous recombinant erythro-poietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81: 956–64.
- Schaefer RM, Schaefer L. Iron monitoring and supplementation: how do we achieve the best results? Nephrol Dial Transplant 1998; 13 Suppl 2: 9 — 12.
- Silva J, Andrade S, Ventura H, Paulo J, Santos L, Colaco S, Oliveira C, Ponce P. Iron supplementa-tion in haemodialysis: practical clinical guidelines. Nephrol Dial Transplant 1998; 13: 2572–7.
- Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in main-tenance haemodialysis patients. Nephrol Dial Transplant 1997; 12: 1173–81.
- Sunder-Plassmann G, Spitzauer S, Hörl WH. The dilemma of evaluating iron status in dialysis patients: limitations of available diagnostic proce-dures. Nephrol Dial Transplant 1997; 12: 1575–80.
- Tarng D, Huang T. Determinants of circulating soluble transferrin receptor level in chronic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1063–9.